Vimal Mehta is CEO & President at BioXcel Therapeutics, Inc. (BTAI). They have made 11 open-market trades across 1 company since 2018, most recently 2026-06-15.
CIK 0001733369
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $89K since 2018, against 3 sales. Across 8 scored buys the stock is up 25.1% at ninety days, and 19.4 points ahead of the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| BTAI | 69,817 | $5K |
Shares reported on the most recent Form 4, priced at the 2026-06-17 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 75% | 50% |
| Avg Move | -4.1% | +9.0% | +25.1% |
| Alpha | -1.6% | +11.0% | +19.4% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BTAI | SELL · 10b5-1 | 2026-05-20 | 2026-05-22 | $1.09 | $21K | +9.3% | +12.8% | -28.9% |
| BTAI | SELL · 10b5-1 | 2024-12-16 | 2024-12-17 | $0.36 | $1K | -6.0% | -11.4% | -63.5% |
| BTAI | SELL · 10b5-1 | 2024-09-16 | 2024-09-17 | $0.69 | $1K | -5.8% | -10.9% | -36.5% |
| BTAI | SELL · 10b5-1 | 2024-06-17 | 2024-06-18 | $1.28 | $3K | -3.3% | +2.5% | -47.1% |
| BTAI | SELL · 10b5-1 | 2024-04-04 | 2024-04-08 | $2.62 | $14K | -1.2% | -17.8% | -58.1% |
| BTAI | SELL · 10b5-1 | 2023-06-15 | 2023-06-16 | $20.86 | $2.5M | -68.1% | -46.4% | -83.0% |
| BTAI | SELL · 10b5-1 | 2023-05-22 | 2023-05-24 | $25.79 | $168K | -20.6% | -27.3% | -84.8% |
| BTAI | SELL | 2023-03-20 | 2023-03-22 | $18.74 | $1.8M | +6.2% | +23.2% | +10.5% |
| BTAI | SELL | 2022-12-15 | 2022-12-19 | $19.69 | $2.4M | +9.5% | +48.2% | -3.9% |
| BTAI | SELL | 2021-06-25 | 2021-06-29 | $30.83 | $29.2M | -7.2% | -13.3% | +5.1% |
| BTAI | BUY | 2019-08-16 | 2019-08-19 | $8.89 | $9K | +13.7% | +26.2% | -33.3% |
| BTAI | BUY | 2019-08-14 | 2019-08-16 | $8.64 | $26K | +0.8% | +14.4% | -52.7% |
| BTAI | BUY | 2019-08-13 | 2019-08-14 | $8.75 | $9K | +8.0% | +21.4% | -48.3% |
| BTAI | BUY | 2018-12-14 | 2018-12-14 | $4.38 | $9K | +14.7% | +51.6% | +149.7% |
| BTAI | BUY | 2018-12-04 | 2018-12-04 | $5.12 | $5K | -24.8% | +1.2% | +79.8% |
| BTAI | BUY | 2018-12-03 | 2018-12-04 | $5.17 | $5K | -24.8% | +1.2% | +79.8% |
| BTAI | BUY | 2018-11-30 | 2018-11-30 | $5.10 | $5K | -16.1% | -22.5% | +70.3% |
| BTAI | BUY | 2018-03-12 | 2021-02-16 | $11.00 | $22K | -4.1% | -21.7% | -44.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.